<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335603</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Mortality Risk and Urinary Proteome Changes in Acute COVID-19 Survivors in the Multinational CRIT-COV-U Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2090</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092090</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Survival prospects following SARS-CoV-2 infection may extend beyond the acute phase, influenced by various factors including age, health conditions, and infection severity; however, this topic has not been studied in detail. Therefore, within this study, the mortality risk post-acute COVID-19 in the CRIT-COV-U cohort was investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Survival data from 651 patients that survived an acute phase of COVID-19 were retrieved and the association between urinary peptides and future death was assessed. Data spanning until December 2023 were collected from six countries, comparing mortality trends with age- and sex-matched COVID-19-negative controls. A death prediction classifier was developed and validated using pre-existing urinary peptidomic datasets.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Notably, 13.98% of post-COVID-19 patients succumbed during the follow-up, with mortality rates significantly higher than COVID-19-negative controls, particularly evident in younger individuals (&lt;65 years). These data for the first time demonstrate that SARS-CoV-2 infection highly significantly increases the risk of mortality not only during the acute phase of the disease but also beyond for a period of about one year. In our study, we were further able to identify 201 urinary peptides linked to mortality. These peptides are fragments of albumin, alpha-2-HS-glycoprotein, apolipoprotein A-I, beta-2-microglobulin, CD99 antigen, various collagens, fibrinogen alpha, polymeric immunoglobulin receptor, sodium/potassium-transporting ATPase, and uromodulin and were integrated these into a predictive classifier (DP201). Higher DP201 scores, alongside age and BMI, significantly predicted death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The peptide-based classifier demonstrated significant predictive value for mortality in post-acute COVID-19 patients, highlighting the utility of urinary peptides in prognosticating post-acute COVID-19 mortality, offering insights for targeted interventions. By utilizing these defined biomarkers in the clinic, risk stratification, monitoring, and personalized interventions can be significantly improved. Our data also suggest that mortality should be considered as one possible symptom or a consequence of post-acute sequelae of SARS-CoV-2 infection, a fact that is currently overlooked.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siwy</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1407-2534</Identifier><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, 30659 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8240-7255</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banasik</LastName><ForeName>Miros&#x142;aw</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0588-1551</Identifier><AffiliationInfo><Affiliation>Department of Nephrology and Transplantation Medicine, Wroc&#x142;aw Medical University, 50-556 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, 413 45 Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Skaraborg Hospital, 541 85 Sk&#xf6;vde, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudoignon</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Saint Louis-H&#xf4;pital Lariboisi&#xe8;re, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, Saint Louis-H&#xf4;pital Lariboisi&#xe8;re, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;lmez</LastName><ForeName>Dilara</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0008-6845-7505</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spasovski</LastName><ForeName>Goce</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nephrology, University Sts. Cyril and Methodius, 1000 Skopje, North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazo</LastName><ForeName>Mercedes Salgueira</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Virgen Macarena Hospital, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajzer</LastName><ForeName>Marek W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>First Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, 30-688 Krak&#xf3;w, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu&#x142;awka</LastName><ForeName>&#x141;ukasz</ForeName><Initials>&#x141;</Initials><Identifier Source="ORCID">0000-0003-4858-2022</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Pathology, Wroclaw Medical University, 50-556 Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Pathology Centre Cellgen, 50-353 Wroc&#x142;aw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzitkowska-Zabielska</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7375-9814</Identifier><AffiliationInfo><Affiliation>Faculty of Physical Education, Gda&#x144;sk University of Physical Education and Sport, 80-336 Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Translational Medicine, Medical University of Gda&#x144;sk, 80-210 Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mischak</LastName><ForeName>Harald</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0323-0306</Identifier><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, 30659 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hecking</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8047-2395</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beige</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kuratorium for Dialysis and Transplantation (KfH) Leipzig, 04129 Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine II, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, St. Georg Hospital Leipzig, 04129 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendt</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1600-6581</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, St. Georg Hospital Leipzig, 04129 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>UriCoV Working Group</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>25323FSB114</GrantID><Agency>Federal Ministry of Health</Agency><Country/></Grant><Grant><GrantID>01KU2309</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant><Grant><GrantID>2022-00542</GrantID><Agency>VINNOVA</Agency><Country/></Grant><Grant><GrantID>PerMed/V/162/UriCov/2023</GrantID><Agency>National Centre for Research and Development</Agency><Country/></Grant><Grant><GrantID>I 6464</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant><Grant><GrantID>ANR-22-PERM-0014</GrantID><Agency>Agence Nationale de la Recherche</Agency><Country/></Grant><Grant><GrantID>I 6471</GrantID><Agency>FWF Austrian Science Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">peptides</Keyword><Keyword MajorTopicYN="N">urine</Keyword></KeywordList><CoiStatement>H.M. is the co-founder and co-owner of Mosaiques Diagnostics. J.S. is employed by Mosaiques Diagnostics GmbH. All other authors declare no conflicts of interest. Authors must identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of reported research results. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335603</ArticleId><ArticleId IdType="pmc">PMC11428519</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092090</ArticleId><ArticleId IdType="pii">biomedicines12092090</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang X., Wang F., Shen Y., Zhang X., Cen Y., Wang B., Zhao S., Zhou Y., Hu B., Wang M., et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. JAMA Netw. Open. 2021;4:e2127403. doi: 10.1001/jamanetworkopen.2021.27403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.27403</ArticleId><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2021 Demographics Collaborators Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950&#x2013;2021, and the impact of the COVID-19 pandemic: A comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989&#x2013;2056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11126395</ArticleId><ArticleId IdType="pubmed">38484753</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., et al. Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Apea V.J., Wan Y.I., Dhairyawan R., Puthucheary Z.A., Pearse R.M., Orkin C.M., Prowle J.R. Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: An observational cohort study. BMJ Open. 2021;11:e042140. doi: 10.1136/bmjopen-2020-042140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-042140</ArticleId><ArticleId IdType="pmc">PMC7813387</ArticleId><ArticleId IdType="pubmed">33455936</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivaldi G., Pfeffer P.E., Talaei M., Basera T.J., Shaheen S.O., Martineau A.R. Long-term symptom profiles after COVID-19 vs. other acute respiratory infections: An analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023;65:102251. doi: 10.1016/j.eclinm.2023.102251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102251</ArticleId><ArticleId IdType="pmc">PMC10721552</ArticleId><ArticleId IdType="pubmed">38106559</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin L., Savale L., Pham T., Colle R., Figueiredo S., Harrois A., Gasnier M., Lecoq A.L., Meyrignac O., Noel N., et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325:1525&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely E.W., Brown L.M., Fineberg H.V. Long Covid Defined. N. Engl. J. Med. 2024 doi: 10.1056/NEJMsb2408466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2408466</ArticleId><ArticleId IdType="pubmed">39083764</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., Levitan E.B., Levy B., McComsey G.A., McCorkell L., Nadkarni G.N., Parthasarathy S., Singh U., et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329:1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou R., Herman E., Ahmed A., Anderson J., Selph S., Dana T., Williams L., Ivlev I. Long COVID Definitions and Models of Care: A Scoping Review. Ann. Intern. Med. 2024;177:929&#x2013;940. doi: 10.7326/M24-0677.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M24-0677</ArticleId><ArticleId IdType="pubmed">38768458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf H.S., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., Blyuss O., Bobkova P., Bonsel G., Borzakova S., et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M.L., King S., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., Khunti K., Alwan N.A., Walker A.S. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 after 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open Forum Infect. Dis. 2022;9:ofac464. doi: 10.1093/ofid/ofac464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. N. Engl. J. Med. 2024;391:515&#x2013;525. doi: 10.1056/NEJMoa2403211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403211</ArticleId><ArticleId IdType="pubmed">39018527</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Boon G.J.A.M., Barco S., Endres M., Geelhoed J.J.M., Knauss S., Rezek S.A., Spruit M.A., Vehreschild J., Siegerink B. The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19. Eur. Respir. J. 2020;56:2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in the Netherlands: An observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Munoz P., Aldamiz T., Diez C., Perez L., Fanciulli C., et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis. 2022;22:211. doi: 10.1186/s12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari M., Hall M., Golubchik T., Ayoubkhani D., House T., MacIntyre-Cockett G., Fryer H.R., Thomson L., Nurtay A., Kemp S.A., et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024;626:1094&#x2013;1101. doi: 10.1038/s41586-024-07029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId><ArticleId IdType="pmc">PMC10901734</ArticleId><ArticleId IdType="pubmed">38383783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Azor A., Atchison C., Trender W., Hellyer P.J., Giunchiglia V., Husain M., Cooke G.S., Cooper E., Lound A., et al. Cognition and Memory after Covid-19 in a Large Community Sample. N. Engl. J. Med. 2024;390:806&#x2013;818. doi: 10.1056/NEJMoa2311330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2311330</ArticleId><ArticleId IdType="pmc">PMC7615803</ArticleId><ArticleId IdType="pubmed">38416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.C., Devason A.S., Umana I.C., Cox T.O., Dohnalova L., Litichevskiy L., Perla J., Lundgren P., Etwebi Z., Izzo L.T., et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851&#x2013;4867. doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Talla A., Vasaikar S.V., Szeto G.L., Lemos M.P., Czartoski J.L., MacMillan H., Moodie Z., Cohen K.W., Fleming L.B., Thomson Z., et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat. Commun. 2023;14:3417. doi: 10.1038/s41467-023-38682-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38682-4</ArticleId><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="pubmed">37296110</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., Dhodapkar R.M., Lu P., Gehlhausen J.R., Tabachnikova A., Greene K., Tabacof L., Malik A.A., et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139&#x2013;148. doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-covid syndrome in individuals admitted to hospital with covid-19, retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Staessen J.A., Wendt R., Yu Y.L., Kalbitz S., Thijs L., Siwy J., Raad J., Metzger J., Neuhaus B., Papkalla A., et al. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: A prospective multicentre cohort study. Lancet Digit. Health. 2022;10:e727&#x2013;e737. doi: 10.1016/S2589-7500(22)00150-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00150-9</ArticleId><ArticleId IdType="pmc">PMC9432869</ArticleId><ArticleId IdType="pubmed">36057526</ArticleId></ArticleIdList></Reference><Reference><Citation>Latosinska A., Siwy J., Mischak H., Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis. 2019;40:2294&#x2013;2308. doi: 10.1002/elps.201900091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elps.201900091</ArticleId><ArticleId IdType="pubmed">31054149</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavrogeorgis E., Mischak H., Latosinska A., Siwy J., Jankowski V., Jankowski J. Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS. Molecules. 2021;26:7260. doi: 10.3390/molecules26237260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26237260</ArticleId><ArticleId IdType="pmc">PMC8658976</ArticleId><ArticleId IdType="pubmed">34885840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantos-Siwy J., Schiffer E., Brand K., Schumann G., Rossing K., Delles C., Mischak H., Metzger J. Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J. Proteome Res. 2009;8:268&#x2013;281. doi: 10.1021/pr800401m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr800401m</ArticleId><ArticleId IdType="pubmed">19012428</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B (Methodol.) 1995;57:125&#x2013;133. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Yekutieli D. The control of the false discovery rate under dependency. Ann. Stat. 2001;29:1165&#x2013;1188. doi: 10.1214/aos/1013699998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aos/1013699998</ArticleId></ArticleIdList></Reference><Reference><Citation>Good D.M., Z&#xfc;rbig P., Argiles A., Bauer H.W., Behrens G., Coon J.J., Dakna M., Decramer S., Delles C., Dominiczak A.F., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell Proteom. 2010;9:2424&#x2013;2437. doi: 10.1074/mcp.M110.001917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M110.001917</ArticleId><ArticleId IdType="pmc">PMC2984241</ArticleId><ArticleId IdType="pubmed">20616184</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmakis D., Koeck T., Mullen W., Parissis J., Gogas B.D., Nikolaou M., Lekakis J., Mischak H., Filippatos G. Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: Feasibility, and clinical and pathogenetic correlates. Eur. J. Heart Fail. 2016;18:822&#x2013;829. doi: 10.1002/ejhf.544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.544</ArticleId><ArticleId IdType="pubmed">27220540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt R., Thijs L., Kalbitz S., Mischak H., Siwy J., Raad J., Metzger J., Neuhaus B., Leyen H.V., Dudoignon E., et al. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine. 2021;36:100883. doi: 10.1016/j.eclinm.2021.100883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100883</ArticleId><ArticleId IdType="pmc">PMC8092440</ArticleId><ArticleId IdType="pubmed">33969282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainous A.G., III, Rooks B.J., Wu V., Orlando F.A. COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk. Front. Med. 2021;8:778434. doi: 10.3389/fmed.2021.778434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.778434</ArticleId><ArticleId IdType="pmc">PMC8671141</ArticleId><ArticleId IdType="pubmed">34926521</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf A.C., Reichardt B., Wagenlechner C., Krotka P., Traxler-Weidenauer D., Mildner M., Mascherbauer J., Aigner C., Auer J., Wendt R. Baseline Drug Treatments and Long-Term Outcomes in COVID-19-Hospitalized Patients: Results of the 2020 AUTCOV Study. medRxiv. 2024 doi: 10.1101/2024.08.22.24312424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.08.22.24312424</ArticleId></ArticleIdList></Reference><Reference><Citation>Oseran A.S., Song Y., Xu J., Dahabreh I.J., Wadhera R.K., de Lemos J.A., Das S.R., Sun T., Yeh R.W., Kazi D.S. Long term risk of death and readmission after hospital admission with covid-19 among older adults: Retrospective cohort study. BMJ. 2023;382:e076222. doi: 10.1136/bmj-2023-076222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-076222</ArticleId><ArticleId IdType="pmc">PMC10475839</ArticleId><ArticleId IdType="pubmed">37558240</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna T.J., Seelye S., Berkowitz T.S., Pura J., Bohnert A.S.B., Bowling C.B., Boyko E.J., Hynes D.M., Ioannou G.N., Maciejewski M.L., et al. Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators: A 2-Year Cohort Analysis. JAMA Intern. Med. 2023;183:1111&#x2013;1119. doi: 10.1001/jamainternmed.2023.3587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.3587</ArticleId><ArticleId IdType="pmc">PMC10442778</ArticleId><ArticleId IdType="pubmed">37603339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M., Xie Y., Topol E.J., Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat. Med. 2024;30:1564&#x2013;1573. doi: 10.1038/s41591-024-02987-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02987-8</ArticleId><ArticleId IdType="pmc">PMC11186764</ArticleId><ArticleId IdType="pubmed">38816608</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama Y., Nakayama M., Abe M., Yokoo T., Minakuchi J., Nitta K. Association between serum beta2-microglobulin and mortality in Japanese peritoneal dialysis patients: A cohort study. PLoS ONE. 2022;17:e0266882. doi: 10.1371/journal.pone.0266882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266882</ArticleId><ArticleId IdType="pmc">PMC9009671</ArticleId><ArticleId IdType="pubmed">35421178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez-Rios G., Katz R., Levitan E.B., Cushman M., Parikh C.R., Kimmel P.L., Bonventre J.V., Waikar S.S., Schrauben S.J., Greenberg J.H., et al. Urinary Biomarkers of Kidney Tubule Health and Mortality in Persons with CKD and Diabetes Mellitus. Kidney360. 2023;4:e1257&#x2013;e1264. doi: 10.34067/KID.0000000000000226.</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0000000000000226</ArticleId><ArticleId IdType="pmc">PMC10547219</ArticleId><ArticleId IdType="pubmed">37533144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina I.K., Mavrogeorgis E., Siwy J., Stojanov R., Mischak H., Latosinska A., Jankowski V. Multiple urinary peptides display distinct sex-specific distribution. Proteomics. 2023;24:e2300227. doi: 10.1002/pmic.202300227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.202300227</ArticleId><ArticleId IdType="pubmed">37750242</ArticleId></ArticleIdList></Reference><Reference><Citation>Drum C.L., Tan W.K.Y., Chan S.P., Pakkiri L.S., Chong J.P.C., Liew O.W., Ng T.P., Ling L.H., Sim D., Leong K.G., et al. Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. J. Am. Heart Assoc. 2017;6:e005586. doi: 10.1161/JAHA.117.005586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.005586</ArticleId><ArticleId IdType="pmc">PMC5669175</ArticleId><ArticleId IdType="pubmed">28611096</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicki M., Siwy J., Wendt R., Lipphardt M., Koziolek M.J., Maixnerova D., Peters B., Kerschbaum J., Leierer J., Neprasova M., et al. Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrol. Dial. Transpl. 2020;37:42&#x2013;52. doi: 10.1093/ndt/gfaa307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaa307</ArticleId><ArticleId IdType="pmc">PMC8719618</ArticleId><ArticleId IdType="pubmed">33313853</ArticleId></ArticleIdList></Reference><Reference><Citation>Didriksson I., Lengquist M., Spangfors M., Leffler M., Sievert T., Lilja G., Frigyesi A., Friberg H., Schiopu A. Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients. J. Intensive Care. 2024;12:26. doi: 10.1186/s40560-024-00740-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-024-00740-4</ArticleId><ArticleId IdType="pmc">PMC11232228</ArticleId><ArticleId IdType="pubmed">38982551</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt-Due A., Pettersen K., Borresdatter-Dahl T., Holter J.C., Gronli R.H., Dyrhol-Riise A.M., Lerum T.V., Holten A.R., Tonby K., Troseid M., et al. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients. J. Intern. Med. 2024;296:80&#x2013;92. doi: 10.1111/joim.13783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13783</ArticleId><ArticleId IdType="pubmed">38539241</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller F., Beige J., Siwy J., Mebazaa A., An D., Mischak H., Schanstra J.P., Mokou M., Perco P., Staessen J.A., et al. Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios. J. Transl. Med. 2023;21:663. doi: 10.1186/s12967-023-04508-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04508-6</ArticleId><ArticleId IdType="pmc">PMC10518109</ArticleId><ArticleId IdType="pubmed">37741989</ArticleId></ArticleIdList></Reference><Reference><Citation>Magalh&#xe3;es P., Pejchinovski M., Markoska K., Banasik M., Klinger M., Svec-Billa D., Rychlik I., Rroji M., Restivo A., Capasso G., et al. Association of kidney fibrosis with urinary peptides: A path towards non-invasive liquid biopsies? Sci. Rep. 2017;7:16915. doi: 10.1038/s41598-017-17083-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17083-w</ArticleId><ArticleId IdType="pmc">PMC5717105</ArticleId><ArticleId IdType="pubmed">29208969</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanese L., Siwy J., Mavrogeorgis E., Amann K., Mischak H., Beige J., Rupprecht H. A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease. Proteomes. 2021;9:32. doi: 10.3390/proteomes9030032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/proteomes9030032</ArticleId><ArticleId IdType="pmc">PMC8293473</ArticleId><ArticleId IdType="pubmed">34287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwy J., Wendt R., Albalat A., He T., Mischak H., Mullen W., Latosinska A., Lubbert C., Kalbitz S., Mebazaa A., et al. CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19, A potential link to molecular pathophysiology? Proteomics. 2021;21:e2100133. doi: 10.1002/pmic.202100133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.202100133</ArticleId><ArticleId IdType="pmc">PMC8420529</ArticleId><ArticleId IdType="pubmed">34383378</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabara Y., Setoh K., Kawaguchi T., Kosugi S., Nakayama T., Matsuda F. Association between serum alpha1-antitrypsin levels and all-cause mortality in the general population: The Nagahama study. Sci. Rep. 2021;11:17241. doi: 10.1038/s41598-021-96833-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96833-3</ArticleId><ArticleId IdType="pmc">PMC8390682</ArticleId><ArticleId IdType="pubmed">34446826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaimes Campos M.A., Andujar I., Keller F., Mayer G., Rossing P., Staessen J.A., Delles C., Beige J., Glorieux G., Clark A.L., et al. Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. Pharmaceuticals. 2023;16:1298. doi: 10.3390/ph16091298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16091298</ArticleId><ArticleId IdType="pmc">PMC10537115</ArticleId><ArticleId IdType="pubmed">37765106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>